Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies

NCT02174263 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02174263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02174263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
February 29, 2016
Completion date
Not reported
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease